Expanding medication assisted therapies in central asia - central asia (CA) represents the most rapidly growing HIV epidemic region worldwide, concentrated in people who inject drugs (pwid) and…
Active Project Grant Awarded Last action
- Award ID
- R01DA054851
- Recipient
-
Yale Univ UEI FL6GV84CKN57
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,914,545
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date 86% complete
- Place of performance
- New Haven, CT 06510, USA
Award details come from USAspending.gov.
Description
Expanding medication assisted therapies in central asia - central asia (CA) represents the most rapidly growing HIV epidemic region worldwide, concentrated in people who inject drugs (pwid) and their sexual partners. Scaling up opioid agonist therapies (OAT) in CA is the most cost-effective strategy to prevent new HIV infections, and more effective when combined with antiretroviral therapy (art). CA countries have especially low OAT (and art) coverage and are uniquely impacted by their proximity to opioid trade routes, a myriad of patient, provider, healthcare and policy barriers and suboptimal implementation. CA countries share a similar rigid semashko healthcare system, which can be especially challenging for implementing evidence-based practices (ebps). Moreover, the HIV treatment cascade differs in the three countries of kazakhstan (KZ), kyrgyzstan (KY) and tajikistan (TJ), generally with low levels of case detection, art prescription and viral suppression. They also differ by OAT coverage, with all being suboptimal and well-below international targets for the 120,500, 25,000 and 22,500 pwid, respectively. We propose to use the network for the improvement of addiction treatment (niatx) implementation strategy to scale-up OAT in three diverse CA countries guided by the epis (exploration-planning-implementation- sustainment) framework. Using our experiences with niatx to scale-up OAT, we will use the epis framework where we will first assess the barriers and facilitators to OAT scale-up, including the inner and outer contexts as well as bridging factors. These findings will guide preparation and implementation efforts using niatx. Collaborative learning is key feature of niatx that can be used in diverse contexts and is an iterative process that promotes change. Understanding the trajectories of implementation, a core feature of epis, may in this context emerge through creating communities of practice, especially when cohesion and/or competence evolves through this process, and may guide other healthcare delivery challenges in the region (e.g., HIV, TB). Using niatx to build important regional expertise and competence and understanding implementation trajectories in this context should help support OAT program sustainability. As part of our implementation and sustainability plan, and consistent with niatx, we will convene stakeholder meetings to bridge inner and outer factors to guide initial and ongoing implementation, review findings from our studies and use information to inform policies for expanding OAT in each CA country. These meeting will inform implementation and guide policy changes to promote sustainability. Significance is justified by the regional needs to prevent HIV in pwid and their sexual partners and the lack of scale-up of ebps. Innovation is enhanced not only by using niatx in a new context, but by more comprehensively understanding scale-up trajectories in this context. Success is likely to be high given the experience of the US and central asian teams, their previous collaborative research and a common goal to control HIV in the region. Public health benefit should be high as findings may mitigate the evolving regional HIV epidemics where OAT has benefits for both primary and secondary HIV prevention.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $383,358 | |
| Amendment | $70,000 | |
| Amendment | $76,762 | |
| Amendment | $74,019 | |
| Amendment | $343,625 | |
| Amendment | $571,007 | |
| Amendment | $572,514 | |
| Amendment | $572,514 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $625,373 | |
| Original award | $625,373 |
Show all 18
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Spid Fond Vostok-Zapad V Kyrgyzskoi Respublike, Of | $74,019 | |
| Tsentr Nauchno-Prakticheskikh Initsiativ | $70,000 | |
| Institute For International Health And Education (Iihe) Inc. | $98,846 | |
| Spid Fond Vostok-Zapad V Kyrgyzskoi Respublike, Of | $94,891 | |
| Tsentr Nauchno-Prakticheskikh Initsiativ | $130,384 | |
| Tsentr Nauchno-Prakticheskikh Initsiativ | $571,383 | |
| Institute For International Health And Education (Iihe) Inc. | $431,976 | |
| Spid Fond Vostok-Zapad V Kyrgyzskoi Respublike, Of | $450,001 |
Quick answers
Who received award R01DA054851?
R01DA054851 was awarded to Yale Univ by National Institute on Drug Abuse (National Institutes of Health) on September 1, 2022.
How much is award R01DA054851 worth?
$3,914,545 has been obligated on R01DA054851.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award